Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide

BACKGROUND: Having performed analytical validation studies, we are now assessing the clinical utility of the upgraded automated Bone Scan Index (BSI) in metastatic castration-resistant prostate cancer (mCRPC). In the present study, we retrospectively evaluated the discriminatory strength of the auto...

Descripción completa

Detalles Bibliográficos
Autores principales: Anand, Aseem, Morris, Michael J., Larson, Steven M., Minarik, David, Josefsson, Andreas, Helgstrand, John T., Oturai, Peter S., Edenbrandt, Lars, Røder, Martin Andreas, Bjartell, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785173/
https://www.ncbi.nlm.nih.gov/pubmed/26960325
http://dx.doi.org/10.1186/s13550-016-0173-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785173/
https://www.ncbi.nlm.nih.gov/pubmed/26960325
http://dx.doi.org/10.1186/s13550-016-0173-z

Ejemplares similares